Chronic Urticaria Drug Landscape
Novartis confirmed on 2026-11-12 that Rhapsido had US approvals for CSU and symptomatic dermographism; leadership here refers to regulatory progress, without a cross-trial efficacy ranking.
Novartis reported on 2026-11-12 that 46.8% of symptomatic dermographism patients originally assigned Rhapsido had a complete or partial response at Week 52 in RemIND.
Celldex said on 2026-11-05 that it expected to submit a CSU application for barzolvolimab in 2027; filing and acceptance could change the regulatory field.
CSU and chronic inducible urticaria (CIndU) are separate populations; response rates across subtypes or trials do not establish an efficacy ranking.
Competitive landscape
| Asset | Company | Mechanism / route | Stage | Indication | Trial identifier | Deal | Latest development | Source |
|---|---|---|---|---|---|---|---|---|
| Rhapsido / remibrutinib | NovartisSwitzerland | BTK inhibitorOral | US approved: CSU / symptomatic dermographism | CSU; subtype-specific CIndU | — | — | RemIND: 25 mg twice daily; SD Week 1 response 41.8% vs 19.2%; original-treatment Week 52 response 46.8% | novartis.com |
| Dupixent / dupilumab | Sanofi / RegeneronFrance / US | IL-4Rα antibodySubcutaneous | US approved | CSU, age 2+, symptomatic despite H1 antihistamines | — | — | Label includes age 2+; prior age-12 threshold is superseded | dailymed.nlm.nih.gov |
| Xolair / omalizumab | Roche / Genentech / NovartisSwitzerland / US | Anti-IgE antibodySubcutaneous | US approved | CSU | — | — | Approved anti-IgE comparator | gene.com |
| barzolvolimab | CelldexUS | Anti-KIT antibodySubcutaneous | Phase 3 results reported; filing planned | CSU; ColdU / dermographism | — | — | CSU Phase 3 endpoints met; 2027 filing planned | ir.celldex.com |
| CUE-221 / UB-221 | Cue / Ascendant / Genesis; originated at United BioPharmaTaiwan origin / China trial / US licensee | Anti-IgE antibodySubcutaneous | Phase 2 results; Phase 2b/3 planned | CSU | — | — | 145 in China Phase 2; no planned statistical comparison with Xolair | cuebiopharma.gcs-web.com |
| lesigercept / YH35324 | YuhanSouth Korea | IgE-trap fusion proteinSubcutaneous | Phase 2 | CSU | jRCT2031260326 | — | Phase 2 registered in Japan; registration is not marketing approval | jrct.mhlw.go.jp |
Taiwan and Asia
Taiwan-origin UB-221 is being developed as CUE-221 outside Greater China; Genesis retains China, Hong Kong, Macau and Taiwan rights. The China Phase 2 enrolled 145 participants; omalizumab was an active comparator without planned statistical testing. Korea’s Yuhan also has a CSU Phase 2 registered in Japan.